Elanco Animal Health Incorporated Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax
Elanco Animal Health Incorporated (ELAN) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-07.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax · last filed 2021-05-07
- Elanco Animal Health Incorporated other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2021-03-31 was $0.00.
- Elanco Animal Health Incorporated other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2020-12-31 was $4.20M.
- Elanco Animal Health Incorporated other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2020-09-30 was -$2.20M.
- Elanco Animal Health Incorporated other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for the quarter ending 2020-06-30 was -$6.00M.
- Elanco Animal Health Incorporated other comprehensive income (loss), cash flow hedge, gain (loss), after reclassification, tax for fiscal 2020 was -$15.40M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 3 month as first filed | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax 12 month |
|---|---|---|---|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $4.20M derived: sum of 2 quarters · filed 2021-05-07 | $2.00M derived: sum of 3 quarters · filed 2021-05-07 | -$4.00M derived: sum of 4 quarters · filed 2021-05-07 | |
| 2020-12-31 | $4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $2.00M derived: sum of 2 quarters · filed 2021-03-01 | -$4.00M derived: sum of 3 quarters · filed 2021-03-01 | -$15.40M 10-K · filed 2021-03-01 | |
| 2020-09-30 | -$2.20M 10-Q · filed 2020-11-06 | -$8.20M derived: sum of 2 quarters · filed 2020-11-06 | -$19.60M 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | -$6.00M 10-Q · filed 2020-07-30 | -$17.40M 10-Q · filed 2020-07-30 | |||
| 2020-03-31 | -$11.00M 10-Q · filed 2021-05-07 | -$11.40M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |